Behandlung des fortgeschrittenen Prostatakarzinoms – eine interdisziplinäre Empfehlung

Bibliografie

• Gillessen S, Attard G, Beer TM, et al.: Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 2018; 73: 178–211. First citation in articleCrossref Medline, Google Scholar

• Stephenson AJ, Bolla M, Briganti A, et al.: Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012; 61: 443–451. First citation in articleCrossref Medline, Google Scholar

• Ghadjar P, Zwahlen D, Aebersold DM, Zimmermann F: Postoperative radiotherapy after radical prostatectomy: indications and open questions. Prostate Cancer 2012; 2012: 963417. First citation in articleCrossref Medline, Google Scholar

• Bolla M, van Poppel H, Tombal B, et al.: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018–2027. First citation in articleCrossref Medline, Google Scholar

• Thompson IM, Tangen CM, Paradelo J, et al.: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. The Journal of urology 2009; 181: 956–962. First citation in articleCrossref Medline, Google Scholar

• Wiegel T, Bartkowiak D, Bottke D, et al.: Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol 2014; 66: 243–250. First citation in articleCrossref Medline, Google Scholar

• Abugharib A, Jackson WC Tumati V , et al.: Very early salvage radiotherapy improves distant metastasis-free survival. J Urol 2017; 197: 662–668. First citation in articleCrossref Medline, Google Scholar

• Tendulkar RD, Agrawal S, Gao T , et al.: Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016; pii: JCO679647 . [Epub ahead of print] First citation in articleGoogle Scholar

• Cornford P, Bellmunt J, Bolla M, et al.: EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017; 71: 630–642. First citation in articleCrossref Medline, Google Scholar

• Network NCC: Prostate Cancer 2017. Verfügbar unter https://www.nccn.org/professionals/physician_gls/f_guidelines.asp; letzter Zugriff am 16.07.2018. First citation in articleGoogle Scholar

• Ghadjar P, Hayoz S, Bernhard J, et al.: Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 2015; 33: 4158–4166. First citation in articleGoogle Scholar

• Carrie C, Hasbini A, de Laroche G, et al.: Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 2016; 17: 747–756. First citation in articleCrossref Medline, Google Scholar

• Shipley WU, Seiferheld W, Lukka HR, et al.: Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 2017; 376: 417–428. First citation in articleCrossref Medline, Google Scholar

• Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 1995; 13: 8–10. First citation in articleCrossref Medline, Google Scholar

• Sweeney CJ, Chen YH, Carducci M, et al.: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737–746. First citation in articleCrossref Medline, Google Scholar

• James ND, Sydes MR, Clarke NW, et al.: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016; 387: 1163–11677. First citation in articleCrossref Medline, Google Scholar

• James N, de Bono JS, Spears MR, et al.: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017; 377: 338–351. First citation in articleCrossref Medline, Google Scholar

• Fizazi N, Tran N, Fein L, et al.: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352–360. First citation in articleCrossref Medline, Google Scholar

• Tannock IF, de Wit R, Berry WR, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512. First citation in articleCrossref Medline, Google Scholar

• Parker C, Nilsson S, Heinrich D, et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223. First citation in articleCrossref Medline, Google Scholar

• de Bono JS, Oudard S, Ozguroglu M, et al.: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154. First citation in articleCrossref Medline, Google Scholar

• de Bono JS, Logothetis CJ, Molina A, et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005. First citation in articleCrossref Medline, Google Scholar

• Ryan CJ, Smith MR, de Bono JS, et al.: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138–148. First citation in articleCrossref Medline, Google Scholar

• Beer TM, Armstrong AJ, Rathkopf DE, et al.: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–433. First citation in articleCrossref Medline, Google Scholar

• Scher HI, Fizazi K, Saad F, et al.: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187–1197. First citation in articleCrossref Medline, Google Scholar

• Mateo J, Carreira S, Sandhu S, et al.: DNA-repair cefects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697–1708. First citation in articleCrossref Medline, Google Scholar

• Schweizer MT, Cheng HH, Tretiakova MS, et al.: Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Oncotarget 2016; 7: 82504–82510. First citation in articleCrossref Medline, Google Scholar

• Padhani AR, Lecouvet FE, Tunariu N, et al.: METastasis reporting and cata system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 2017; 71: 81–92. First citation in articleCrossref Medline, Google Scholar

• Saad F, Gleason DM, Murray R, et al.: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879–882. First citation in articleCrossref Medline, Google Scholar

• Fizazi K, Carducci M, Smith M , et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813–822. First citation in articleCrossref Medline, Google Scholar

• Gillessen S, Omlin A, Attard G, et al.: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26: 1589–1604. First citation in articleCrossref Medline, Google Scholar